Navigation Links
Antibody therapy lengthens survival of metastatic melanoma patients in large clinical trial
Date:6/7/2010

CHICAGOA therapy that multiplies the effect of a natural disease-fighting antibody has extended the lives of patients with metastatic melanoma in a large, international clinical trial. The study's researchers will report their findings simultaneously at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago and in the New England Journal of Medicine.

Patients in the phase III clinical study who received the drug ipilimumab a monoclonal antibody made by duplicating a single type of human antibody thousands of times over survived for an average of 10 months whether they received the drug alone or in combination with a therapeutic vaccine known as gp100, compared to just over six months for those who received gp100 alone, investigators found. The four-month difference represents a 67 percent increase in survival time between the two groups. And because it occurred in patients who were otherwise out of treatment options all of them having metastatic disease that spread even after earlier treatment the treatment demonstrates the promise of monoclonal antibody treatment for cancer patients not helped by conventional therapies, the study authors say.

F. Stephen Hodi, MD, director of the melanoma treatment center at Dana-Farber Cancer Institute and co-first author of the paper, says the findings are significant on two levels. "It is the first study to show a survival benefit for metastatic melanoma, which is often a fatal disease, and it is proof that this first-in-class treatment is effective in cancer."

The study (Abstract 4) will be presented in a plenary session at ASCO on Sunday, June 6, 1-4 pm, N Hall, Room B1, and will be posted on the Internet in advance of print publication by the New England Journal of Medicine.

The number of cases of metastatic melanoma considered the most serious form of skin cancer has increased during the past 30 years, and its death rate is rising faster than mo
'/>"/>

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-233-5507
Dana-Farber Cancer Institute
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Antibody-guided drug shows encouraging activity in metastatic breast cancer
2. Fox Chase clinical trial tests first of its kind antibody
3. Targeted therapy prolongs life in patients with HER2-positive breast cancer
4. PharmMD Secures Investments to Fund New Opportunities in Medication Therapy Management
5. More smokers kick the habit with extended nicotine patch therapy, Penn research shows
6. Experts Issue Warning on Prostate Hormone Therapy
7. ASGCT: Gene Therapy Shows Promise for Patients with Pompe Disease
8. AAPM statement on quality radiation therapy
9. Congress Urged to Take Immediate Action to Ensure Frail Patients Continue to Receive Critical Therapy Services
10. Intensive Insulin Therapy Wont Boost Septic Shock Survival
11. News brief: Dermatologic infections in cancer patients treated with EGFRI therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... U.S. Pharmacopeial Convention is pleased to announce that Gigi ... North Carolina State’s College of Veterinary Medicine has been ... Distinguished Volunteer Service—the organization’s highest award. , Since ... experts to direct its work to improve the health ...
(Date:1/22/2015)... Hollywood, California (PRWEB) January 22, 2015 The City ... 2015 at 10 a.m., to commemorate the 42nd anniversary of the ... United States. , “It’s been 42 years since the Roe vs. ... choose is still as present as ever,” said City of West ...
(Date:1/22/2015)... AZ (PRWEB) January 22, 2015 Padre Murphy's ... long supporter of Pro Player Health Alliance (PPHA). ... Padre Murphy's in getting everyone, including NFL greats, treated for ... of the leading groups supporting the cause in the valley. ...
(Date:1/22/2015)... (PRWEB) January 23, 2015 Angelweddingdress is a ... business invites its customers to follow it on Facebook, Twitter, ... a Valentine’s Day gift. Angelweddingdress draws a lottery every week. ... Sale to Feb. 28, 2015. Click Angelweddingdress homepage ...
(Date:1/22/2015)... New York (PRWEB) January 22, 2015 The ... ) in the U.S. District Court, Southern District of West ... Bard, Inc. in that proceeding’s first bellwether trial. In an ... for a new trial after finding that C.R. Bard had ...
Breaking Medicine News(10 mins):Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 2Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 3Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 4Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4
... of doctors and their patients with diabetes do not see ... manage, according to a survey by the University of Michigan ... and hypertension among their top concerns, 38 percent of doctors ... while only 18 percent of diabetics said it was the ...
... ... a distribution agreement to provide GuardRFID’s Active RFID platform to its Healthcare, Government and ... ... with VT Milcom of Virginia Beach, Va. to provide its next generation RFID platform ...
... , ... Feb. 2 Hospitals in the Boston area ... (ICUs) prevent central-line bloodstream infections, a cause of death, disability, and ... February 2 , www.ConsumerReportsHealth.org will post hospital infection rates ...
... , RANCHO CORDOVA, Calif. , ... the delivery of eyecare and eyewear through innovative business solutions ... Jr. as its chief financial officer. Ball will replace ... recently retired after 31 years, and report to chief executive ...
... ... Hospitals in Los Angeles vary dramatically in terms ... a cause of death, disability, and expense in our nations, hospitals that ... post hospital infection rates for 41 Los Angeles area hospitals, ...
... ... patient safety information in the public eye , YONKERS, N.Y. ... Tampa / St. Petersburg area vary dramatically in terms of how ... of death, disability, and expense in our nations, hospitals that is largely ...
Cached Medicine News:Health News:Diabetes patients rank health concerns differently than their doctors, U-M survey shows 2Health News:Guard RFID Solutions Inc. and VT Milcom Enter into Distribution Agreement 2Health News:Consumer Reports Health: Central-Line Infection Rates In Boston Hospitals Vary Dramatically; Some Hospitals Not Reporting 2Health News:Consumer Reports Health: Central-Line Infection Rates In Boston Hospitals Vary Dramatically; Some Hospitals Not Reporting 3Health News:Consumer Reports Health: Central-Line Infection Rates In Boston Hospitals Vary Dramatically; Some Hospitals Not Reporting 4Health News:Consumer Reports Health: Central-Line Infection Rates In Boston Hospitals Vary Dramatically; Some Hospitals Not Reporting 5Health News:Consumer Reports Health: Central-Line Infection Rates In Boston Hospitals Vary Dramatically; Some Hospitals Not Reporting 6Health News:Consumer Reports Health: Central-Line Infection Rates In Boston Hospitals Vary Dramatically; Some Hospitals Not Reporting 7Health News:VSP Global Appoints New Chief Financial Officer 2Health News:Consumer Reports Health: Central-Line Infection Rates in Los Angeles Hospitals Vary Dramatically; Some Hospitals Not Reporting 2Health News:Consumer Reports Health: Central-Line Infection Rates in Los Angeles Hospitals Vary Dramatically; Some Hospitals Not Reporting 3Health News:Consumer Reports Health: Central-Line Infection Rates in Los Angeles Hospitals Vary Dramatically; Some Hospitals Not Reporting 4Health News:Consumer Reports Health: Central-Line Infection Rates in Los Angeles Hospitals Vary Dramatically; Some Hospitals Not Reporting 5Health News:Consumer Reports Health: Central-Line Infection Rates in Los Angeles Hospitals Vary Dramatically; Some Hospitals Not Reporting 6Health News:Consumer Reports Health: Central-Line Infection Rates in Los Angeles Hospitals Vary Dramatically; Some Hospitals Not Reporting 7Health News:Consumer Reports Health: Central-Line Infection Rates in Los Angeles Hospitals Vary Dramatically; Some Hospitals Not Reporting 8Health News:Consumer Reports Health: Central-Line Infection Rates in Tampa-St. Petersburg Area Hospitals Vary Dramatically 2Health News:Consumer Reports Health: Central-Line Infection Rates in Tampa-St. Petersburg Area Hospitals Vary Dramatically 3Health News:Consumer Reports Health: Central-Line Infection Rates in Tampa-St. Petersburg Area Hospitals Vary Dramatically 4Health News:Consumer Reports Health: Central-Line Infection Rates in Tampa-St. Petersburg Area Hospitals Vary Dramatically 5Health News:Consumer Reports Health: Central-Line Infection Rates in Tampa-St. Petersburg Area Hospitals Vary Dramatically 6
(Date:1/23/2015)... Jan. 23, 2015 Cord Blood America, Inc. ( www.cordblood-america.com ... the "Company")  filed a Preliminary Proxy Statement, Schedule 14A, with ... and provides an update for shareholders detailing why a "YES" ... Dear Shareholders, As we reflect upon ...
(Date:1/23/2015)... Gem Pharmaceuticals announced today that the initial soft ... Company,s Phase 2 clinical trial.  This open-label study will ... GPX-150 (an investigational medication), in approximately 30 adults as ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO GPX-150 ...
(Date:1/22/2015)... 22, 2015  BiOptix is pleased to announce the appointment ... of Chemistry and Biochemistry. Scott joins the company after previous ... Amgen throughout the course of his nearly 20 year ... is a nationally recognized thought leader in the biosensor ...
Breaking Medicine Technology:Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
... Trellis Infusion Catheter enables the physician to ... fluid, and disperse the agent by means ... Trellis is a multi-lumen catheter with two ... and infusion holes located between these balloons. ...
... ACRYSOF® UV-absorbing acrylic foldable single-piece posterior chamber ... of the human crystalline lens in the ... years of age and older. The optical ... soft acrylic material. These lenses have biconvex ...
... All USIOL lenses are manufactured ... and processes. Perspex CQ UV ... the multi-piece and single piece ... available in both nonphaco and ...
Single piece PMMA lens, AC depth: 4.9, 2 suture holes....
Medicine Products: